✦ LIBER ✦

Is ERBB-2 A predictive marker for response to primary chemotherapy for operable breast cancer: a prospective study in a phase ii randomized trial of doxorubicin/cyclophosphamide (AC) and doxorubicin/paclitaxel (AT)

✍ Scribed by P. De Crémoux; V. Diéras; V. Le Doussal; A. Vincent-Salomon; M. Tubiana-Hulin; J.-Y. Pierga; F. Spyratos; H. Magdelénat; P. Pouillart

Book ID: 117667263
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 120 KB
Volume: 35
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(99)80713-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views